Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 2, 2024 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Tuesday January 9, 2024 in San Francisco. Kevin Gorman, Chief Executive Officer, will present at the conference.
Related news for (NBIX)
- Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules
- Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results
- Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington’s Disease Chorea
- Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden
- Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder